Ale, thanks for that great detective work on candy and using a different alias on the abmd board. Here is a cut and paste from 2013, where one poster was onto topcvdude
Hey TopCVdude - nice to see you're still around. For all who don't remember this guy, he is a sales rep for a competing product. He has consistently bashed ABMD for many years. I have issues with ABMD's management, but I'm just an investor. TopCVdude is not. He's a shill for a competitor. So his "good luck" wish is rather sarcastic. Just FYI. Less
11,000 shares traded of OSIR in 1.5 hours, nobody cares. If every employee of Stryker just bought 1000 shares of OSIR we would be gong somewhere.
Popcorn is good, at any rate, feels like it is ready to move one way or another. Think we will know shortly as the bands are very tight....
If making the comment that we are fully loaded is not the kiss of death, I don't know what is. When there is no one left to buy, like yelling fire in a crowded movie theater. I would go long on a break of 18 on volume, until then in range from 13 to 17.
This is when you should be glad no one cares about OSIR, markets down 1.75 percent and 3000. Shares traded for OSIR after 20 minutes ,
You are delusional with those comments, the volume tells the story and this stock has no volume, no interest. Could be moved either way if volume showed up, until then this is just noise fluttering in the wind.
This is horrible, 2200 shares traded in one hour, people are just jumping off of buildings, going to be a rough day with all of this volume
Buy on the rumor, sell on the news. Will take a year to see any revenue from Stryker. Interesting the deal is exclusive, which shuts out any further deals, with that said Stryker is blue chip and validation for OSIR.
Last one to leave please shut off the lights, bond holders are about to own a mess of Texas acreage, zaza bankruptcy is in play...
Remember while oil prices drop, nearly 1/2 of zaza's production is natural gas which has held steady. I agree with either a buyout or major joint venture plays in the works. Also should have some news on refinancing the debt soon.
Raymond James guy just called bottom in oil stocks just now on cnbc, Zaza gets taken out soon, someone keeps hitting the bid all morning, naked shorts will get killed in this little stock
I think Zaza is doing all of this settling of agreements because they are getting ready to take an offer for the company.
In conclusion, these factors scratch the surface of how MiMedx is starting to climb its way to being the leader in biological wound care, just as Petit has done with a number of companies before this. Institutional awareness has been jolted awake after the open demonstration and inclusion into the company's developments on Analyst Day. Despite the recent pop in the few days following the Analyst Day, MDXG has still yet to regain yearly highs, so the upside potential and growth story are very largely intact. Considering that the wound market is only one part of the company's portfolio; with surgical, orthopedics and sports medicine as further drivers of growth, Petit's own metric for valuation being 10x 2015 revenue seems fair. Using that metric puts the stock at a sweet spot around $16.50, or a cool 100% upside to current prices. I would say that would be a very nice first step for investors as we join MDXG in its climb to the top.
Current treatments using dermal grafts already exist in the forms of Apligraf® and Dermagrafts, the former being derived from living cells, and the latter being a scaffold of human fibroblasts. Both of these current treatments work by providing a matrix to attract epithelial and skin cells close to the wound in order to close it. In a retrospective study by MiMedx comparing EpiFix® to Apligraf® and Dermagraft (see here), the superiority of EpiFix® is surprisingly clear. For Apligraf® and Dermagraft, the rates of complete healing are low (92% EpiFix® vs. 56% and 30% for Apligraf® and Dermagraft , respectively), the time it takes to get to that healing is extensive (12 weeks vs. 2-6 weeks for EpiFix), and the cost per patient is rather sizable ($3,091 vs. $7097 vs. $11,881, respectively).
In addition to these differences, Apligraft® and Dermagraft require special handling and shipping requirements, need to be frozen for storage and then thawed making them difficult to use, and limited sizes of the grafts on the larger side, results in a high percentage of waste these products produce. The underlying reason for why MiMedx has such a superior product is that they have been able to process these placental tissues in a number of optimizing ways that are patent protected that other competitors cannot or will not be able to replicate.
First, they are able to maintain the structural integrity of the multiple amnion and chorion layers during separation (See Figure 1). Second, they dehydrate the tissue allowing it to preserve almost all of the growth factors present (See Figure 2). Lastly, the dehydrated, active forms of these grafts can be stored at room temperature for up to five years versus needing to be constantly refrigerated or frozen. For a striking study directly comparing the differences between multi-layer grafts versus a would-be competitor's single-layer graft
Epifix doesn't use any human embryonic stem cells. It acts as a stem cell magnet to let your body use it's own stem cells for healing. That is the huge advantage over OSIR as it's frozen living cells dies with out acting as a stem cell magnet.
That has to be the most stupid question asked in years on this board. You are obviously short or you did zero research before opening your mouth, either way we have this great tool that just came out called the internet, go do your homework please..
Not a good sign when a former comptroller dumps 100 percent of his OSIR holding. Either sour grapes or he knows something. Chart looks like this is going to single digits soon, I will buy some then. Until then, volume is pathetic.
Because some idiot put in a market order for 1000 shares to a thinly traded stock that no one cares about but us, then said thank you very much.